Payment overview · 2025
General Payments
$482.67
24 reported records · 14 companies
Healthcare provider profile · identity verified
Aaron Everett Mitschke, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LIBERTY, ME · NPI 1831450063
Verified facts
What the public records show
CMS Open Payments records show Aaron Everett Mitschke, FNP received $482.67 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $79.75 | 16.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.97 | 10.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $48.04 | 9.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.72 | 8.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.98 | 7.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.46 | 7.1% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $30.40 | 6.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.77 | 6.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.62 | 5.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.30 | 5.2% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $21.95 | 4.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.59 | 4.5% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $17.84 | 3.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.28 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $482.67 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $50.97 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $48.04 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.46 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.64 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $30.40 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.77 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.68 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.68 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $25.30 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 54 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 37 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
51 | 17 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 302 | 86 |
| Trazodone Hcl | Trazodone Hcl | 274 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 266 | 74 |
| Gabapentin | Gabapentin | 247 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 203 | 65 |
| Furosemide | Furosemide | 197 | 58 |
| Montelukast Sodium | Montelukast Sodium | 185 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 54 |
| Lisinopril | Lisinopril | 158 | 47 |
| Meloxicam | Meloxicam | 150 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 29 |
| Losartan Potassium | Losartan Potassium | 128 | 42 |
| Potassium Chloride | Potassium Chloride | 127 | 35 |
| Tramadol Hcl | Tramadol Hcl | 119 | 39 |
| Alprazolam | Alprazolam | 118 | 39 |
| Metformin Hcl | Metformin Hcl | 117 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 32 |
| Ozempic | Semaglutide | 90 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 28 |
| Bupropion Xl | Bupropion Hcl | 85 | 21 |
| Glimepiride | Glimepiride | 83 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 21 |
| Omeprazole | Omeprazole | 76 | 22 |
| Sertraline Hcl | Sertraline Hcl | 76 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 57 |
| Prednisone | Prednisone | 67 | 50 |
| Myrbetriq | Mirabegron | 66 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 65 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 21 |
| Clonazepam | Clonazepam | 60 | 19 |
| Azithromycin | Azithromycin | 58 | 46 |
| Lorazepam | Lorazepam | 57 | 14 |
| Carvedilol | Carvedilol | 56 | 20 |
| Mounjaro | Tirzepatide | 55 | 11 |
| Jardiance | Empagliflozin | 54 | 13 |
| Allopurinol | Allopurinol | 52 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 32 |
| Eliquis | Apixaban | 51 | 17 |
| Ezetimibe | Ezetimibe | 51 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 11 |
| Clonidine Hcl | Clonidine Hcl | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 19 |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 44 | 12 |
| Meclizine Hcl | Meclizine Hcl | 42 | 16 |
| Ondansetron Odt | Ondansetron | 42 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 41 | 12 |
| Simvastatin | Simvastatin | 41 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 18 |
| Cephalexin | Cephalexin | 37 | 30 |
| Linzess | Linaclotide | 37 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Methocarbamol | Methocarbamol | 36 | 12 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 11 |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Famotidine | Famotidine | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 27 |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | 13 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | 12 |
| Nystatin | Nystatin | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 18 |
| Gemtesa | Vibegron | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 13 |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 24 |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Mupirocin | Mupirocin | 14 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Droplet Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $482.67 · 24 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, CREON, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, INSPIRE, JARDIANCE, LINZESS, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Senza, UBRELVY, VRAYLAR, WATCHMAN FLX, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error